Autodesk Inc vs AstraZeneca plc — how do they compare? Autodesk Inc trades at $247.6 (market cap $53.12B), while AstraZeneca plc trades at $158.6 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 4.7× Autodesk Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | AZN | |
|---|---|---|
Market Cap | $53.12B | $248.14B |
Sector | Technology | Health |
52-Week High | $326.79 | $209.48 |
52-Week Low | $187.72 | $147.06 |
Enterprise Value | $52.92B | $275.41B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.
The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →